Novartis’ Afinitor Gets EU Approval to Treat Pancreatic Tumors
The European Commission is expanding the indication for Novartis’ Afinitor to include treatment of advanced pancreatic neuroendocrine tumors (PNET) following the FDA’s May approval for the indication.
300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.
Phone (703) 538-7600 - Fax (703) 538-7676 - Toll free (888) 838-5578.
Copyright by FDAnews. All rights reserved. Do not duplicate or redistribute in any form.